INVOLIN
DEAD

Serial Number

76307432

Owner

Cellectis S.A.

Attorney

Barry L. Kelmachter

Filing Date

Aug 30, 2001

Add to watchlist:

No watchlists yet
View on USPTO

INVOLIN Trademark

Serial Number: 76307432 • Registration: 2954070

INVOLIN is a trademark filed by Cellectis S.A. on August 30, 2001. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Cellectis S.A. (9 trademarks)

8 rue de la Croix
Paris 75013 , FR

Entity Type: 16

Trademark Details

Filing Date

August 30, 2001

Registration Date

May 24, 2005

Published for Opposition

May 4, 2004

Cancellation Date

December 30, 2011

Goods & Services

Pharmaceutical, veterinary and health-care products, namely polypeptides for in vivo and in vitro genetic engineering for clinical use; natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease for clinical use; cells engineered by meganuclease recombination systems for clinical use; microorganism cultures and preparations for clinical medical use, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, and nucleic acid vectors; microorganism cultures and preparations for use as human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and microorganisms used for producing therapeutic compounds or vaccines; bacteriological preparations for clinical medical use, namely bacteriologic preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases and nucleic acid vectors; bacteriological preparations for use as human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; drugs for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; biological preparations for clinical medical use, namely polypeptides for in vivo in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemical biochemical preparations for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease, and cells engineered by meganuclease recombination systems; chemical and biochemical preparations for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemopharmaceutical products

chemical, biochemical, biotechnological products intended for industry, the sciences, agriculture, and horticulture, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research use; cells engineered by meganuclease recombination systems for scientific, laboratory or medical research; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research; deoxyribonucleic acid reagents for scientific research use, namely for the transport of biological molecules; microorganism cultures and preprations for use in the manufacture of human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; microorganisms used for producing therapeutic compounds or vaccines; microorganism cultures and preparations for medical research use, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for medical research use, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for use in the manufacture of human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of reagents and endocnuclease

Scientific and industrial research; research in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research in chemistry, biology, biochemistry, molecular biology, and bacteriology; research and development for others of techniques of biochemical analysis, biological analysis, and molecular biology techniques; scientific transgenesis research of deoxyribonucleic acid for the preparation or conveying of biological molecules; scientific analysis namely in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research and development for others of new molecules intended for industry; laboratory research in the fields of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; medical services; studies of technical projects in the field of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; testing, analysis and evaluation of engineering works for others; licensing of patents and intellectual property; computer programming for others, development for others of multimedia software programs

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 30, 2011 C8..
REGISTERED-PRINCIPAL REGISTER
May 24, 2005 R.PR
OPPOSITION TERMINATED NO. 999999
Mar 25, 2005 OP.T
OPPOSITION DISMISSED NO. 999999
Mar 25, 2005 OP.D
OPPOSITION INSTITUTED NO. 999999
Sep 9, 2004 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jun 2, 2004 ETOF
PUBLISHED FOR OPPOSITION
May 4, 2004 PUBO
NOTICE OF PUBLICATION
Apr 14, 2004 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 10, 2004 CNSA
CASE FILE IN TICRS
Oct 18, 2003 CFIT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 8, 2003 CRFA
FAX RECEIVED
Oct 8, 2003 FAXX
CONTINUATION OF FINAL REFUSAL MAILED
Oct 3, 2003 CNCF
PREVIOUS ACTION COUNT WITHDRAWN
Sep 16, 2003 ZZZY
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sep 15, 2003 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
May 20, 2003 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2003 CRFA
CONTINUATION OF FINAL REFUSAL MAILED
May 7, 2003 CNCF
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 10, 2003 CRFA
PAPER RECEIVED
Mar 10, 2003 MAIL
FINAL REFUSAL MAILED
Nov 15, 2002 CNFR
Sec. 1(B) CLAIM DELETED
Nov 14, 2002 1.BD
ASSIGNED TO EXAMINER
Oct 8, 2002 DOCK
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 6, 2002 CRFA
NON-FINAL ACTION MAILED
Nov 9, 2001 CNRT
ASSIGNED TO EXAMINER
Nov 2, 2001 DOCK